Saturday 17 October 2026
Export CYAD’s income statement to Excel — free account
Celyad SA
CYAD Healthcare Biotechnology
Celyad SA’s revenue for fiscal 2025 (year ended December 2025) was $23,800.00, down 88.2% from fiscal 2024.
Follow CYAD
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | 88 | 87 | 96 | 107 | 93 | 101 | 39 | 19 | 19 | 5 | ||||
| Revenue/emp, $m | 0.11 | 0.05 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 9 | 4 | 4 | 0 | 0 | — | — | 0 | 0 | 0 | ||||
| Gross margin, % | 99.38 | 85.45 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | 32.34 | 93.54 | 61.76 | |||||
| EBT | (26) | (64) | (44) | (32) | (20) | (31) | (43) | (9) | (6) | 1 | |||||
| EBT margin, % | (277.04) | (1,593.09) | (1,201.51) | (478,758.21) | (344,773.68) | 0.00 | 0.00 | (8,343.75) | (3,130.75) | 3,945.80 | |||||
| Net income | (26) | (64) | (44) | (32) | (20) | (31) | (43) | (9) | (6) | 1 | |||||
| Depreciation | 2 | 10 | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 1.01 | 0.42 | 0.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (2.80) | (6.62) | (3.97) | (2.57) | (1.40) | (2.01) | (1.91) | (0.36) | (0.15) | 0.02 | |||||
| Cash flow | (2.93) | (5.22) | (2.89) | (2.52) | (2.27) | (2.02) | (1.31) | (0.64) | (0.15) | (0.18) | |||||
| Capex | (0.20) | (0.10) | (0.18) | (0.06) | (0.01) | (0.03) | (0.01) | 0.02 | 0.00 | 0.08 | |||||
| Free cash flow | (3.14) | (5.32) | (3.07) | (2.58) | (2.27) | (2.05) | (1.31) | (0.62) | (0.15) | (0.10) | |||||
| Book value | 10.80 | 5.58 | 5.89 | 4.08 | 2.54 | 3.31 | 0.20 | 0.27 | 0.01 | 0.06 | |||||
| Shares, m | 9 | 10 | 11 | 13 | 14 | 16 | 23 | 26 | 41 | 44 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | |||||
| P/B | 0.00 | 0.00 | 0.00 | 3.94 | 3.07 | — | — | — | — | — | |||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | |||||
| EV/FCF | 0.93 | 0.31 | 0.49 | (1.60) | (0.94) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (27) | (50) | (32) | (32) | (32) | (32) | (30) | (16) | (6) | (8) | ||||
| Capex | (2) | (1) | (2) | (1) | 0 | 0 | 0 | 0 | 0 | 3 | |||||
| Free cash flow | (29) | (51) | (34) | (32) | (32) | (32) | (30) | (16) | (6) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 82 | 32 | 50 | 35 | 9 | 24 | 5 | 9 | 4 | 2 | ||||
| Total debt | 1 | 1 | 1 | 4 | 3 | 2 | 0 | 1 | 1 | — | |||||
| Net debt | (90) | (37) | (57) | (40) | (17) | (33) | (13) | (7) | (4) | (2) | |||||
| Shareholders’ equity | 101 | 54 | 66 | 51 | 35 | 52 | 5 | 7 | 1 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (15.80) | (52.82) | (44.40) | (30.26) | (22.32) | (36.89) | (74.78) | (47.63) | (44.44) | 12.04 | ||||
| ROIC | (169.87) | (225.64) | (340.22) | (190.46) | (65.05) | (107.45) | 0.00 | (2,616.94) | 0.00 | 75.63 | |||||
| ROE | (23.29) | (82.62) | (74.05) | (54.94) | (45.44) | (72.08) | (153.55) | (160.82) | (170.87) | 56.72 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · fundamentals updated 14 Oct 2026
Charts ten years each
Celyad SA vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MCRB Seres Therapeutics, Inc. | $25.2M | — (loss-making) | — (loss-making) | +96.79% (above 0%: growing) | n/m | −66.15% (below 0%: shrinking) | 100.00% | (2,890.35%) | Compare |
| ABVC ABVC BioPharma, Inc. | $24.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $23.9M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CYAD Celyad SA | $23.8M | — (loss-making) | — (loss-making) | — | n/m | +78.72% (above 0%: growing) | 0.00% | 0.00% | |
| PLRZ Polyrizon Ltd. | $23.7M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| IMMP Prima BioMed Ltd | $23.7M | — (loss-making) | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.4M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $23.3M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| CNTX Context Therapeutics Inc. | $22.1M | — (loss-making) | — | — | n/m | −20.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $23.7M | — | — | +7,343.49% | — | −61.42% | 100.00% | 0.00% |
Celyad SA (CYAD) key facts
- Concern: Celyad SA’s revenue for fiscal 2025 (year ended December 2025) was $23,800.00, down 88.2% from fiscal 2024.
- Celyad SA (CYAD) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- Return on equity was 56.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 for fiscal 2025.
Celyad SA (CYAD) Latest News
No news at this impact. Lower the threshold for more.